|
07 Jun 2007 |
Anacor clinical study of AN2728, a novel anti-inflammatory compound, shows efficacy in psoriasis
|
|
07 Jun 2007 |
Movetis Announces Start of a Phase IIa Trial for M0002 in Ascites
|
|
07 Jun 2007 |
Surface Logix Starts Phase 2a Clinical Trial of SLx-4090 in Dyslipidemia
|
|
07 Jun 2007 |
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
|
|
06 Jun 2007 |
Phase 2 results for EentreMmed’s Ppanzem® NCD brain cancer study presented at ASCO
|
|
06 Jun 2007 |
Biovitrum terminates preclinical program in obesity. All rights are returned by GlaxoSmithKline
|
|
06 Jun 2007 |
Sunesis Pharmaceuticals Receives Preclinical Milestone Payment from SARcode Corporation
|
|
05 Jun 2007 |
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
|
|
05 Jun 2007 |
Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
|
|
05 Jun 2007 |
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
|
|
05 Jun 2007 |
Cardiome and Astellas Announce Positive Results from ACT 2 Trial
|
|
05 Jun 2007 |
Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
|
|
05 Jun 2007 |
Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
|
|
05 Jun 2007 |
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
|
|
05 Jun 2007 |
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
|
|
05 Jun 2007 |
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
|
|
05 Jun 2007 |
GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders
|
|
05 Jun 2007 |
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
|
|
05 Jun 2007 |
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
|
|
05 Jun 2007 |
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
|
|
05 Jun 2007 |
NPS Announces Progression of the Calcilytics Development Program in Osteoporosis by GlaxoSmithKline
|
|
05 Jun 2007 |
ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
|
|
04 Jun 2007 |
Tapestry Pharmaceuticals presents Phase I data on TPI 287 at the 43rd ASCO Annual Meeting
|
|
04 Jun 2007 |
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
|
|
04 Jun 2007 |
Vical Demonstrates Safety and Tolerability of IL-2 DNA Delivery with Electroporation
|
